360 related articles for article (PubMed ID: 16357130)
1. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM
Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407
[TBL] [Abstract][Full Text] [Related]
4. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
[TBL] [Abstract][Full Text] [Related]
6. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
Izeradjene K; Douglas L; Delaney AB; Houghton JA
Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
[TBL] [Abstract][Full Text] [Related]
7. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
9. The TRAIL DISCussion: It is FADD and caspase-8!
Peter ME
Cell Death Differ; 2000 Sep; 7(9):759-60. PubMed ID: 11042670
[No Abstract] [Full Text] [Related]
10. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
[TBL] [Abstract][Full Text] [Related]
11. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Martin S; Phillips DC; Szekely-Szucs K; Elghazi L; Desmots F; Houghton JA
Cancer Res; 2005 Dec; 65(24):11447-58. PubMed ID: 16357153
[TBL] [Abstract][Full Text] [Related]
13. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
17. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
18. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
[TBL] [Abstract][Full Text] [Related]
19. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
20. TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX; Ogawa O; Kakehi Y
Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]